Alzheimer's Disease Education and Referral Center

Search for Clinical Trials

Your Search Identified 79 Trial(s):

  • 1. ABT-126 in Subjects with Mild to Moderate Alzheimer's Disease
  • 2. Cataract Removal and Alzheimer's Disease
  • 3. BIIB037 in Prodromal or Mild Alzheimer's Disease
  • 4. AZD3480 for Mild to Moderate Dementia of the Alzheimer's Type
  • 5. Carvedilol in Alzheimer's Disease
  • 6. ABT-126 in Subjects with Alzheimer's Disease on Acetylcholinesterase Inhibitors
  • 7. Mild Cognitive Impairment and Obstructive Sleep Apnea (MEMORIES)
  • 8. Pharmacological Management of Delirium (PMD)
  • 9. Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
  • 10. Comparative Research of Alzheimer's Disease Drug (COMET-AD)
  • 11. BAN2401 for Early Alzheimer's Disease
  • 12. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia (DIAN TU)
  • 13. Gantenerumab for Prodromal Alzheimer's Disease
  • 14. ELND005 for Agitation and Aggression in Alzheimer's Disease
  • 15. Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
  • 16. Home-Delivered Intervention for Depressed, Cognitively Impaired Elders
  • 17. Tailored Activity Program-VA
  • 18. Preventing Cognitive Decline in African Americans with Mild Cognitive Impairment
  • 19. Composite MR Neuroimaging Marker for Alzheimer's Disease
  • 20. Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI)
  • 21. Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
  • 22. Systolic Blood Pressure Intervention Trial: Memory and Cognition in Decreased Hypertension (SPRINT-MIND)
  • 23. ADvance Deep Brain Stimulation in Patients with Mild Probable Alzheimer's Disease
  • 24. Fit & Active Seniors Trial (FAST)
  • 25. Effects of Simvastatin on Biomarkers
  • 26. Aerobic Exercise in Early Alzheimer's Disease
  • 27. Effects of EVP-0962 on Amyloid Levels in Cerebrospinal Fluid
  • 28. PET Imaging Agent [18F]AZD4694 in Probable Alzheimer's Disease
  • 29. Implications of Amyloid Pathology
  • 30. Effects of Mental Stimulation in Patients with Mild Cognitive Impairment
  • 31. Effects of Atomoxetine in Mild Cognitive Impairment
  • 32. Improving Dementia Caregiver Sleep and the Effect on Heart Disease Biomarkers
  • 33. TRx0237 for Mild Alzheimer's Disease
  • 34. AC-1204 for Mild to Moderate Alzheimer's Disease
  • 35. AZD3293 to Treat Alzheimer's Disease
  • 36. Aerobic Exercise Training in Mild Cognitive Impairment
  • 37. Arterial Spin Labeling (ASL) MRI for Cognitive Decline
  • 38. Effects of Fruitflow-II and Resveratrol on Memory, Fitness, and Cerebral Blood Flow
  • 39. Alzheimer's Disease Genetics Study
  • 40. Alzheimer's Disease Multiple Intervention Trial
  • 41. Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)
  • 42. Aspirin in Reducing Events in the Elderly (ASPREE)
  • 43. Conversations as a Means to Delay Alzheimer's Disease Onset
  • 44. Dominantly Inherited Alzheimer Network (DIAN)
  • 45. Exendin-4 for the Treatment of Alzheimer's Disease
  • 46. Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia
  • 47. Imaging of Cognition, Learning, and Memory in Aging
  • 48. Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
  • 49. PhytoSERMs for Menopause Symptoms and Age-Associated Memory Decline
  • 50. Educational Video to Improve Nursing Home Care in End-Stage Dementia
  • 51. MK-8931 for Mild to Moderate Alzheimer's Disease
  • 52. Dietary Supplementation with Anatabloc® in Alzheimer's Disease
  • 53. Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia
  • 54. Intravenous Immunoglobulin (IGIV), 10% in Alzheimer´s Disease
  • 55. RG1662 in Individuals with Down Syndrome
  • 56. RO4602522 in Patients with Moderate Alzheimer Disease on Donepezil or Rivastigmine Therapy
  • 57. Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Mild Alzheimer's Disease
  • 58. PF-05212377 for People with Alzheimer's Disease and Neuropsychiatric Symptoms
  • 59. Thinking, Walking Outcomes by Type of Exercise
  • 60. AAB-003 (PF-05236812) in Alzheimer's Disease
  • 61. Exercise, Age-Related Memory Decline, and Hippocampal Function
  • 62. Cognitive Benefits of Aerobic Exercise Across the Age Span
  • 63. Screening and Evaluation of Patients with Signs and Symptoms of Alzheimer's Disease
  • 64. Memory Consolidation in Obstructive Sleep Apnea
  • 65. Florbetapir (18F) PET Imaging Effectiveness in Management of Patients with Cognitive Decline
  • 66. Language in Primary Progressive Aphasia
  • 67. Living with Frontotemporal Dementia
  • 68. Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Other Dementias
  • 69. 4 Repeat Tauopathy Neuroimaging Initiative
  • 70. Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease, and Controls
  • 71. Memory and Thinking Problems in Older Adults After Surgery
  • 72. Neuroimaging in Frontotemporal Dementia
  • 73. COGNISION™ as a Useful Cognitive Biomarker for Alzheimer's Disease
  • 74. Genes, Exercise, Memory, and Neurodegeneration
  • 75. Combination Treatment Study for Memory Impairment and Depression
  • 76. LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or in Mild Alzheimer's Disease
  • 77. Effects of Aging and Estrogen on Memory and Cognition
  • 78. Caregiver Stress: Interventions to Promote Health and Well-being
  • 79. AVP-923 for Treatment of Agitation in Alzheimer's Patients

    • Return to AD Clinical Trials Search Results

    Return to AD Clinical Trials Home

    Refine Your Search

    Type in a word or phrase such as drug name,
    disease stage, or trial name
    Input a city and state or zip code
    Enter the distance in number of miles from the location
    (default is 50)
    Age of the participant